AVEO Oncology Highlights Recent Progress and 2021 Outlook

 – Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch –

– Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 –

– Corinne D. Epperly, MD, MPH, Appointed to Board of Directors –

– Phase 2 Open Label Randomized Study of Ficlatuzumab in HNSCC Enrollment Complete; Plans to Announce Results and Phase 3 Decision on Track for Mid-2021 –

– AV-380 Phase 1 Clinical Study Initiated Following FDA’s IND Acceptance –

https://www.businesswire.com/news/home/20210107005248/en/AVEO-Oncology-Highlights-Recent-Progress-and-2021-Outlook